0001209191-23-018460.txt : 20230314 0001209191-23-018460.hdr.sgml : 20230314 20230314162250 ACCESSION NUMBER: 0001209191-23-018460 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230310 FILED AS OF DATE: 20230314 DATE AS OF CHANGE: 20230314 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WAGNER CHARLES F JR CENTRAL INDEX KEY: 0001223348 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 23731320 MAIL ADDRESS: STREET 1: C/O MILLIPORE CORP CITY: BILLERICA STATE: MA ZIP: 01820 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-03-10 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001223348 WAGNER CHARLES F JR C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP & Chief Financial Officer Common Stock 2023-03-10 4 S 0 361 286.64 D 57772 D Common Stock 2023-03-10 4 S 0 515 287.83 D 57257 D Common Stock 2023-03-10 4 S 0 327 288.91 D 56930 D Common Stock 2023-03-10 4 S 0 30 289.44 D 56900 D Common Stock 2023-03-10 4 S 0 541 291.47 D 56359 D Common Stock 2023-03-10 4 S 0 185 292.68 D 56174 D Common Stock 2023-03-10 4 S 0 27 293.61 D 56147 D Common Stock 2023-03-10 4 S 0 102 294.94 D 56045 D Common Stock 2023-03-13 4 S 0 24 288.31 D 56021 D Common Stock 2023-03-13 4 S 0 420 292.41 D 55061 D Common Stock 2023-03-13 4 S 0 1153 293.35 D 54448 D Common Stock 2023-03-13 4 S 0 715 294.52 D 53733 D Common Stock 2023-03-13 4 S 0 292 295.89 D 53441 D Common Stock 2023-03-13 4 S 0 62 296.77 D 53379 D Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $286.64 (range $286.17 to $287.16). Open market sales reported on this line occurred at a weighted average price of $287.83 (range $287.30 to $288.20). Open market sales reported on this line occurred at a weighted average price of $288.91 (range $288.37 to $289.34). Open market sales reported on this line occurred at a weighted average price of $291.47 (range $291.10 to $292.00). Open market sales reported on this line occurred at a weighted average price of $292.68 (range $292.14 to $293.12). Open market sales reported on this line occurred at a weighted average price of $294.94 (range $294.85 to $295.35). Open market sales reported on this line occurred at a weighted average price of $292.41 (range $291.97 to $292.82). Open market sales reported on this line occurred at a weighted average price of $293.35 (range $292.99 to $293.80). Open market sales reported on this line occurred at a weighted average price of $294.52 (range $294.13 to $294.81). Open market sales reported on this line occurred at a weighted average price of $295.89 (range $295.33 to $296.32). /s/ Christiana Stevenson, Attorney-in-Fact 2023-03-14